Pop Biotechnologies Inc.

Pop Biotechnologies Inc., a self-certified small disadvantaged business manufacturer headquartered in Buffalo, New York, develops vaccine and immunotherapy platforms based on nanoliposome particle technology and operates as a prime recipient on federal research grants awarded by the National Institutes of Health and National Cancer Institute.

The company's core platform is SNAP (Spontaneous Nanoliposome Antigen Particle), a liposome-display system built on cobalt porphyrin-phospholipid (COPOP) chemistry that incorporates adjuvants—monophosphoryl lipid A and QS-21—to elicit immune responses. Pop Biotechnologies uses SNAP to formulate multivalent vaccine candidates targeting infectious diseases and chronic conditions. Recent grant-funded work spans influenza, fungal infection, cancer, atherosclerosis, and Alzheimer's disease. The company received a $599,806 Small Business Innovation Research contract from the National Institute of Allergy and Infectious Diseases (NIAID) in September 2023 for development of multivalent QS-18 protein nanoparticles for broadly protective influenza vaccine, with performance ending September 29, 2025. Under SBIR Phase II from NIAID in June 2024 (award running through May 31, 2027), Pop Biotechnologies is advancing a hexavalent adjuvanted influenza platform (SNAP-FLU) for dose sparing and rapid deployment, in partnership with the University at Buffalo, BioQual, and Texas Biomedical Research Institute. An August 2024 Phase II SBIR grant from NIAID (completion July 31, 2027) funds development of a liposome-displayed peptide vaccine against disseminated candidiasis, targeting multidrug-resistant Candida auris. A Phase I Small Business Technology Transfer grant from the National Heart, Lung, and Blood Institute (NHLBI) awarded $309,794 in August 2026 addresses development of a liposome-displayed apolipoprotein B fragment vaccine for atherosclerosis immunotherapy, partnering with Cedars-Sinai. Pop Biotechnologies also received Phase II SBIR funding from the National Cancer Institute (April 2024, completion March 31, 2026) for clinical translation of light-activated nanoparticulate doxorubicin (PhotoDOX) for hepatocellular carcinoma, with an FDA pre-IND meeting completed in 2019. The National Institute on Aging funded Phase I SBIR (September 2023, completion May 31, 2028) and Phase II STTR (September 2023, completion July 31, 2025) grants for SNAP-AD, a multivalent mosaic vaccine targeting amyloid-beta and tau epitopes simultaneously for Alzheimer's disease treatment.

Pop Biotechnologies serves five federal agencies, with the National Institute of Allergy and Infectious Diseases accounting for 6 awards and $1.2 million in combined potential value—the entirety of the vendor's disclosed federal grant potential value. The National Cancer Institute and National Institute on Aging account for 4 and 2 awards respectively. The vendor holds no named federal contract vehicles and no active commercial-services SCI records after FY2023, when it invoiced approximately $600 thousand across 1.7 FTEs on SCI-reportable service contracts. Four awards carry completion dates within the next twenty-four months and face recompete exposure. Pop Biotechnologies operates as a prime on 93% of recent federal awards and subcontracts to other federal recipients; it received one grant sub-award from Applied Research Institute Inc. in July 2026. The company engages no subcontractors on SCI-reportable prime contracts (0% sub-hours share). Government-paid rates on SCI service contracts median around $164.67 per hour, consistent across the small invoiced base. Pop Biotechnologies competes exclusively on set-asides and grant programs reserved for small disadvantaged businesses and Small Business Innovation Research, with no full-and-open competition in the disclosed footprint.